February 3, 2025
Imaging Biometrics Expands Distribution with Blackford
Imaging Biometrics, LLC (IB), Elm Grove, WI, a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), has amended their existing distribution agreement with AI platform provider Blackford Analysis Ltd (Blackford). The amendment adds IB Nimble, IB ASL, IB FTB, and IB FTB Express to the agreement, allowing Blackford to also sell these products to their growing global client base.
Acquired by Bayer in early 2023, Blackford is a pioneer in the healthcare AI platform and solutions sphere, offering healthcare providers a pathway to a comprehensive list of 140+ curated AI applications from various trusted vendors via a trusted centralized platform point of entry. This approach simplifies accessibility and streamlines the integration and deployment of advanced AI technology, optimizing workflows and ultimately benefiting patient care.
IB Nimble remains an independent mobile application but will interface with Blackford’s Enterprise AI platform. Compatible with both iOS and Android, it facilitates secure, real-time collaboration among multi-disciplinary medical experts-a technology of high interest to Blackford.
“We see strong growth potential in using mobile technology across the healthcare enterprise. IB Nimble has the ability to connect key clinicians through secure, real-time collaboration. By enhancing communication and streamlining treatment decisions, it ultimately supports more effective and efficient patient care,” says Ben Panter, Founder and CEO of Blackford.
IB ASL is a new product that incorporates arterial spin labeling (“ASL”). Available via a Blackford platform integration, ASL is a perfusion approach that complements IB Neuro. Instead of using an injected contrast agent, ASL uses the body’s own blood. Its clinical application has grown particularly for measuring blood flow (as opposed to blood volume) in the care of patients who suffered a stroke.
The FTB mapping technologies, which offer exclusive benefits to neuro-oncologists and surgeons for the treatment of vascular brain tumors like glioblastoma and brain metastases, are available through Blackford’s AI platform.
“We appreciate Blackford’s continued interest in our quantitative applications like FTB mapping, and are excited for the early and strong interest of IB Nimble,” said Michael Schmainda, CEO of IB.
-ENDS-
The Directors of the Company accept responsibility for the contents of this announcement.
For further information, please contact:
|
IQ-AI Ltd Trevor Brown/Al Musella/Brett Skelly/Michael Schmainda Tel: 020 7469 0930 |
|
Peterhouse Capital Limited (Financial Adviser and Broker) Tel: 020 7220 9797 |
About Imaging Biometrics® LLC
IB is a wholly owned subsidiary of IQ-AI Limited, (LSE: IQAI), delivering quantitative imaging platforms and therapeutics which transform how clinicians diagnose and treat patients, making them more efficient and effective. For more information about Imaging Biometrics, visit the company’s website at www.imagingbiometrics.com. Follow IB on X @IQAI_IB.
About Blackford Analysis, Ltd
Blackford are pioneers in the radiology AI space, with over a decade of experience working in partnership with leading hospitals and ground-breaking technology providers. We operate as an Enterprise AI partner, providing access to a tried-and-tested core platform, tailored services, and a portfolio of 140+ applications to help healthcare providers unlock the value of AI and improve patient outcomes.
Our collaboration and arms-length acquisition by Bayer ensures that our customers and partners have the support and long-term security needed to underpin successful AI strategies.
To learn more about Blackford’s tailored approach to AI solutions visit www.blackfordanalysis.com, and follow us on X and LinkedIn.